Blog

Sharesight20ASX top 20 ASX trades - 18th November 2019

by Angela Thompson, Senior Digital Marketing Manager, Sharesight | Nov 18th 2019
The below article is for informational purposes only and does not constitute a product recommendation, or taxation or financial advice and should not be relied upon as such. Please consult with your financial adviser or accountant to obtain the correct advice for your situation.

Afterpay (ASX: APT) was the most traded ASX stock by Sharesight users over the past week, followed by Novita Healthcare Ltd (ASX: NHL), and Imugene Limited (ASX: IMU).

Top 20 ASX trades last week

Click on the image below to see the full Sharesight20ASX snapshot of the 20 most traded ASX shares during the period:

Top20 ASX trades Nov 18th 2019

Subscribe to Sharesight20 snapshots

Did you know you can receive Sharesight20 trading snapshots by email automatically? Subscribe here to always get the latest data when it's released.

Track your investment portfolio with Sharesight

Get access to Sharesight20 insights like this by tracking your investment portfolio with Sharesight. Built for the needs of investors like you:

Sign up for a FREE Sharesight account and get started tracking your investments today.

FURTHER READING

Track RRSP RRIF in Sharesight

Track your RRSP and RRIF in Sharesight

by Stephanie Stefanovic | Mar 27th 2026

Canadian investors can automatically track their Registered Retirement Savings Plan (RRSP) and Registered Retirement Income Fund (RRIF) accounts in Sharesight.

Family office technology

The family office problem that most investment tools can't solve

by Stephanie Stefanovic | Mar 26th 2026

Managing a family office portfolio means tackling complexity most investment tools weren't built for. There's a better way to track your wealth.

Why women should invest2

Why women should invest differently

by Morningstar Australia | Mar 23rd 2026

A new video from Morningstar shares research on why engagement matters and how informed participation can improve long-term investment outcomes for women.